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Objectives: To evaluate the clinical and economic burden of head and neck squamous cell
carcinoma (HNSCC) in France.
Methods: All 53,255 incident adult patients discharged with a ﬁrst diagnosis of HNSCC in
2010–2012 were identiﬁed from the 2008–2013 French National Hospital Discharge (PMSI)
database. We conducted a retrospective longitudinal analysis of prognosis and direct costs
attributable to HNSCC.
Results: Direct medical costs attributable to HNSCC care amounted to 665 million euros in
2012 in France. The majority (62%) of incident patients were 64 years old or less at HNSCC
diagnosis and incurred 1.3-fold higher mean direct costs as compared to elderly patients
(41,909 vs 32,221 euros over 3 years, respectively; p<0.001). HNSCC stage at initial
treatment was the major driver of mean (SD) direct costs over 3 years (p<0.001): 19,819
(23,150) euros in 31% patients diagnosed at early stage; 46,791 (34,841) euros in 60%
patients diagnosed at locally advanced stage; and 43,377 (33,953) euros in 9% patients
diagnosed with distant metastasis. About half patients died over 3 years at a median (IQR)
age of 63 (56–75) years resulting in 10.9 years-of-life lost on average per incident patient.
Conclusion: The present study suggests that the clinical and economic burden of HNSCC is
substantial in France.
Keywords: head and neck squamous cell carcinoma, prognosis, costs, burden of disease,
National Hospital discharge database
Introduction
Head and neck squamous cell carcinoma (HNSCC) involve various primary cancer
sites from nasopharynx to larynx that are overall frequent with an estimated pre-
valence of 1.4 million adults affected in high-income countries in 2015.1,2 HNSCC
remain overall of poor prognosis,3 and recent marketing of new immunotherapy is
expected to lower the burden of HNSCC.4,5 However, early cost-effectiveness ana-
lyses conducted in the US and UK suggest that routine use of immunotherapy in
HNSCC is most likely unaffordable in high-income countries.6,7,8 While cost-effec-
tiveness analyses raise global concerns about price and long-term effects of immu-
notherapy, their generalizability to various health-care settings may have been
overlooked as large variations are expected in direct cost estimates of HNSCC care.
A recent review on the economic burden of HNSCC pointed out that most cost
studies were conducted in US Medicare patients aged 65+ years old with limited
generalizability to the most frequent groups of middle-aged or European patients.9
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In particular, tobacco smoking and heavy drinking are the
main risk factors for HNSCC and account for larger popu-
lation attributable fractions in Europe (84.3%, 95% CI:
72.6–90.3) as compared to North America (50.5%, 95%
CI: 34.2–62.2).10 As both risk factors also involve frequent
comorbidities all along HNSCC care, including second
primary cancers,11 direct costs of HNSCC care may be
relatively higher in Europe.12 In addition, about 60% of
patients are diagnosed at a locally advanced stage3 and
receive combined-modality treatments to decrease the risk
of relapse.13 To the best of our knowledge, only one study
disentangled direct costs by phase-of-care in oropharynx
cancer and found that relapse treatment was associated
with dramatic increases in direct costs as compared to
initial treatment.14 Such heterogeneity in both prognosis
and costs depending on relapse occurrence does matter for
cost-effectiveness models but cannot be assessed from cost
studies limited to HNSCC stage at diagnosis.9
In this study, we identiﬁed all incident cases of
HNSCC discharged from French hospitals in the years
2010 to 2012 and assessed the clinical and economic
burden of HNSCC at three levels: prevalent direct costs
attributable to HNSCC care in 2012 in France; clinical
outcomes and direct costs over 3 years, overall and by
HNSCC stage at initial treatment; and monthly direct costs
by phase-of-care including relapse treatment.
Materials and methods
Data source
The data source was the French National Hospital
Discharge (PMSI) database in the years 2008–2013. The
database contains all public and private hospital claims for
acute and post-acute care. The standardized discharge
summary includes: patient’s demographics (gender, age,
postal code of residency); primary and associated dis-
charge diagnosis codes according to the WHO
International Classiﬁcation of Diseases, tenth revision
(ICD-10); medical procedures performed; length of stay,
entry and discharge modes (including in-hospital death).
Using unique anonymous identiﬁers, we conducted a retro-
spective longitudinal analysis of prognosis and direct costs
attributable to HNSCC care.15,16
Study population
We included all adults residing in metropolitan France and
discharged with a primary or associated discharge
diagnosis code of HNSCC (ICD-10: C00-C06; C09-C14;
C30.0; C31; C32) in the years 2008–2012 (see the full
coding dictionary in Supplementary Table S1). To mini-
mize a possible misclassiﬁcation bias of a relapse case as
an incident case, we excluded all patients ﬁrst diagnosed
with HNSCC in 2008–2009 or recorded with a personal
history of cancer at ﬁrst diagnosis of HNSCC in 2010–
2012.17 For all selected patients, hospital discharge data of
the year 2013 were used to ascertain vital status and reﬁne
direct costs until ﬁxed censoring at July 1, 2013 (see
Supplementary Methods and Tables S1–S4).
HNSCC characteristics
Primary HNSCC sites were identiﬁed from the primary
discharge diagnosis recorded at ﬁrst HNSCC surgery or
panendoscopy, and disentangled in eight categories: nasal
cavity/paranasal sinuses; nasopharynx; lip; oral cavity; oro-
pharynx; hypopharynx; larynx; and ill-deﬁned HNSCC.18
All patients entered an initial treatment phase covering
the ﬁrst six months after HNSCC diagnosis.14,19 We con-
sidered three cancer stages independent of the primary
HNSCC site: distant metastasis stage; locally advanced
stage; and early stage.18 A distant metastasis stage was
identiﬁed by any record of distant metastasis during initial
treatment. A locally advanced stage was deﬁned by any
discharge diagnosis indicating locoregional extension or
any initial treatment eliminating an early stage (eg, che-
motherapy). An early stage was recorded by default for
other patients.
After six months, patients identiﬁed at locally
advanced or early stage became at risk of relapse.
Relapse was identiﬁed by the ﬁrst hospital record of a
local relapse of the primary HNSCC site or any new
event indicative of extension (distant metastasis, locore-
gional extension, or chemotherapy). Patients who relapsed
were followed over a relapse treatment phase (starting at
ﬁrst hospital record of relapse); other patients were fol-
lowed by default over a continuing care phase (starting at
six months after HNSCC diagnosis).
The Charlson Comorbidity Index (CCI)20 is the most
widely used comorbidity index in HNSCC care21 and we
identiﬁed each comorbidity with use of ICD-10 coding algo-
rithms validated in large hospital discharge databases22 includ-
ing the French National Hospital Discharge database.23
Patients were categorized at each phase-of-care (initial treat-
ment, relapse treatment, or continuing care) according to a
CCI of 0; 1; 2; or ≥3.
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Direct costs attributable to cancer care
Of all 1,012,500 hospital stays recorded for the study
population, 877,544 (86.7%) were attributable to cancer
care following the methodology developed by the French
National Cancer Institute.24 Hospital expenses are reim-
bursed according to national Diagnosis-Related Group
(DRG)-related tariffs that vary by year and public/private
sector. Since national DRG-related tariffs showed minor
(±1%) variations by year, we relied on the national DRG-
related tariffs of the year without adjustment on inﬂation.
In addition, national DRG-related tariffs are lower in the
private sector as compared to the public sector because
medical procedures are directly reimbursed to physicians
in the private sector. Therefore, we relied on national
DRG-tariffs of the public sector to fully assess hospital
expenses in the private sector. Hospital stays were cate-
gorized with use of the DRG classiﬁcation system to
disentangle several main cost categories:24 diagnostic
workup; surgery (including reconstructive surgery); radia-
tion therapy; chemotherapy (including actual expenses of
targeted therapy cetuximab); supportive care (including
adverse effects of treatments); and palliative care (from
ﬁrst record of palliative care onwards).
Radiation therapy is usually performed in an outpatient
setting. In the public sector, radiation therapy is also
reimbursed with use of national DRG-tariffs. In the private
sector, radiation therapy is directly reimbursed to physi-
cians and cannot be identiﬁed in the hospital discharge
database. However, all modality treatments other than
radiation therapy administered in the private sector were
observed in the study population. Therefore, we used
HNSCC management recommendations by primary
HNSCC site13 to impute the administration of radiation
therapy in the private sector: a) in patients diagnosed at
early stage and treated with exclusive radiation therapy (ie,
patients identiﬁed without surgery or radiation therapy in
the public sector); and b) in patients diagnosed at locally
advanced stage and treated with combined chemotherapy
and radiation therapy (ie, patients identiﬁed with che-
motherapy and without radiation therapy in the public
sector) (Supplementary Table S2). We relied on the aver-
age costs of radiation therapy in the public sector for
patients initially treated at early or locally advanced
stage to value the administration of radiation therapy
imputed in the private sector. No imputation was per-
formed at other phases-of-care (ie, initial treatment with
distant metastasis; relapse treatment) as radiation therapy
is less frequently administered and usually performed in
the public sector.
Medical transportation to/from hospital was estimated
for each hospital stay with use of the minimum kilometric
distance between the postal code of residency and hospital
address.25 We considered two medical transportations per
hospital stay (only one if the patient died at hospital) and
the distribution of transportation mode (ambulance: 39%;
light health vehicle: 20%; taxi: 37%; other 4%).26 Medical
transportation was valued following French Social
Security reimbursement rules based on transportation
mode and kilometric distance. Regarding radiation therapy
imputed in the private sector, medical transportation costs
were estimated from the average costs of medical trans-
portation in the public sector for patients receiving radia-
tion therapy at early or locally advanced stage.
Statistical analyses
Prevalent direct costs of HNSCC care in France were
estimated for the year 2012 that accrued the largest sample
size with patients followed at all phases-of-care
(n=32,987). Direct costs were summed over the year
2012, overall and according to payer, hospital ﬁeld, hospi-
tal sector, or main cost category.
Per-patient clinical outcomes and direct costs were
estimated over 3 years in all patients diagnosed in the
ﬁrst semester of 2010 with complete follow-up
(n=9,714). Clinical outcomes assessed included: death
rate over the follow-up; median (IQR) age at death; and
average years-of-life lost per patient that combines death
rate, age at death, and years-of-life lost with reference to
the life table of the 2015 Global Burden of Disease
Study.27 Mean (SD) direct costs were estimated over an
exact follow-up of 3 years. Per-patient clinical outcomes
and direct costs were compared by demographics and
HNSCC characteristics.
Monthly direct costs were estimated by phase-of-care
in the overall study population (n=53,255).14,19 Direct
costs were summed over by patient and phase-of-care,
overall and by main cost category. Since zero cost may
be recorded for a main cost category, we used two-part
models to estimate monthly costs by phase-of-care. Each
two-part model combined the probability of non-zero costs
(logistic regression) and the mean (SD) monthly estimate
of non-zero costs (general linear model with gamma dis-
tribution) with adjustment on demographics and HNSCC
characteristics.28,29
Dovepress Schernberg et al
ClinicoEconomics and Outcomes Research 2019:11 submit your manuscript | www.dovepress.com
DovePress
443
 
Cl
in
ico
Ec
on
om
ics
 a
nd
 O
ut
co
m
es
 R
es
ea
rc
h 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
7.
94
.1
34
.7
6 
on
 2
7-
Au
g-
20
19
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Results
Prevalent direct costs attributable to
HNSCC care in 2012 in France
Direct costs attributable to HNSCC care amounted to 665
million euros in 2012. About all (98%) direct costs were
covered by the French Social Security (Figure 1). Direct
costs were primarily driven by acute care (88%) and bore
by the public sector (69%).
Curative-intent treatments of HNSCC accounted for
356 (54%) million euros in 2012 and were related to
surgery (37%), chemotherapy (36%), and radiation therapy
(27%). Radiation therapy imputed in the private sector
accounted for 45% of all radiation therapy costs. Actual
expenses of targeted therapy cetuximab accounted for 28%
of all chemotherapy costs, 10% of curative-intent treat-
ment costs, and 5% of prevalent direct costs.
Medical transportation to/from hospital amounted to 76
(11%) million euros and was primarily driven by radiation
therapy (73%) and then chemotherapy (18%).
Per-patient clinical outcomes and direct
costs over 3 years
The characteristics of 9,714 patients diagnosed with
HNSCC in the ﬁrst semester of 2010 and complete fol-
low-up over 3 years are presented in Table 1. Overall, 4,456
(45.9%) patients died over 3 years at a median (IQR) age of
63 (56–75) years resulting in 10.9 years-of-life lost on
average per incident patient. HNSCC care was associated
with mean direct costs of 38,212 euros over 3 years.
The majority (62%) of incident patients was 64 years
old or less at HNSCC diagnosis. HNSCC care was 1.3-
fold more costly in middle-aged patients as compared to
elderly patients (41,909 vs 32,221 euros over 3 years,
respectively; p<0.001). A late stage at initial treatment
(locally advanced or distant metastasis) or an increased
number of comorbidities was associated with poorer prog-
nosis and increased mean direct costs over 3 years.
Clinical outcomes and monthly costs of
HNSCC by phase-of-care
The characteristics of all 53,255 incident patients diag-
nosed with HNSCC in the years 2010 to 2012 are pre-
sented by phase-of-care in Table 2. As compared to
patients initially treated at early stage (29.6%), patients
at locally advanced stage (61.4%) had a higher death rate
in the ﬁrst six months (10.4% vs 16.2%, p<0.001) and
then a higher relapse rate in the follow-up (13.4% vs
32.5% at 18 months, p<0.001). Respectively, direct
costs per month were 2.4-fold higher at initial treatment
(2,566 vs 6,263 euros on average per month) and then
12.2-fold higher from relapse onwards (435 vs 5,320
euros on average per month).
Main cost categories showed marked differences by
phase-of-care (Figure 2). Curative-intent treatment and
related medical transportation accounted for the majority
of direct costs at the initial treatment phase in patients at
early stage (1,419 euros per month; 55.7%) or locally
advanced stage (4,190 euros per month; 66.5%).
Curative-intent treatment and related medical transporta-
tion accounted for a minority of direct costs in patients
with distant metastasis at initial treatment (2,947 euros per
month; 40.3%) or relapsing in the follow-up (2,333 euros
per month; 44.3%) as the majority of direct costs was
explained by supportive care (about 23%) and palliative
care (about 31%). Actual expenses of targeted therapy
cetuximab reached a maximum after relapse (973 euros
per month; 18.5%).
Discussion
In this nationwide study of all incident cases of HNSCC
diagnosed in French hospitals in the years 2010 to 2012,
we found that HNSCC incurred a substantial clinical and
economic burden in France. Direct costs attributable to
HNSCC care amounted overall to 665 million euros in
2012. Most (70%) patients were initially treated at a late
stage with poor prognosis and increased direct costs.
HNSCC incurs a substantial clinical burden of disease
in France with an average of 10.9 years-of-life lost per
incident patient. Several studies corroborate that the clin-
ical burden of HNSCC may reach a peak in France. In the
2015 Global Burden of Disease study, French patients with
HNSCC were estimated with the highest exposure levels
to both tobacco smoking and heavy drinking among high-
income countries.2,30 French men were also recorded with
the highest incidence rates of HNSCC31 as well as the
highest HNSCC-speciﬁc mortality rates.32,33
Only one study reported prevalent direct cost estimates
for HNSCC care in France with use of the same data
source for the year 2007.34 In comparison, the economic
burden of HNSCC had seemingly doubled in ﬁve years
from 323 million euros in 2007 to 665 million euros in
2012. Differences between the two studies are most likely
related to study design and scope of direct costs. The
previous cost study used a cross-sectional design limited
Schernberg et al Dovepress
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to hospital stays with a discharge diagnosis of HNSCC. In
contrast, we conducted a retrospective longitudinal analy-
sis to encompass all hospital stays attributable to cancer
care after HNSCC diagnosis, irrespective of HNSCC
recording in the follow-up.24 In addition, we took into
account all direct costs related to hospital care including
post-acute care (12%), out-of-pocket expenses for inpati-
ent stays (2%), and medical transportation to/from hospital
(11%). Differences between the two studies are unlikely
related to valuation methods. National DRG-related tariffs
for HNSCC care remained stable from 2008 to 2013. Also,
radiation therapy costs in the private sector were imputed
in both studies. In the previous cost study, radiation
therapy costs in the public sector were roughly inﬂated
according to the case-mix of public/private radiation ther-
apy for all cancer care. In contrast, we individualized
imputation by primary HNSCC site and stage. However,
imputation of radiation therapy in the private sector
accounted for <7% of prevalent direct costs.
Inference from cost studies conducted in US Medicare
patients aged 65+ years old may not be warranted to other
populations of HNSCC patients.9 The majority (62%) of
incident HNSCC patients were 64 years old or less in
France, and we found that direct costs over 3 years were
1.3-fold higher in middle-aged patients as compared to
elderly patients. In particular, HNSCC diagnosis in
Table 1 Per-patient clinical outcomes and direct costs over 3 years
Characteristics of incident patients
diagnosed with HNSCC in the ﬁrst
semester of 2010
N (%) Death rate
over 3
years, n (%)
Age at
death,
median
(IQR)
Years-of-
life lost,
mean (SD)
Direct costs
over 3 years,
mean (SD)
All patients 9,714 (100) 4,456 (45.9) 63 (56–75) 10.9 (13.8) 38,212 (33,924)
Gender
Men 7,614 (78.4) 3,592 (47.2) 63 (56–73) 11.4 (13.9) 39,537 (34,059)
Women 2,100 (21.6) 864 (41.1) 68 (56–81) 8.9 (13.3) 33,412 (32,997)
Age at HNSCC diagnosis
<65 years old 6,008 (61.9) 2,470 (41.1) 57 (52–61) 13.0 (16.0) 41,909 (35,513)
65+ years old 3,706 (38.1) 1,986 (53.6) 76 (70–83) 7.4 (7.9) 32,221 (30,236)
HNSCC site at diagnosis
Nasal cavity / paranasal sinuses 497 (5.1) 223 (44.9) 75 (64–83) 8.0 (11.7) 30,711 (28,977)
Nasopharynx 326 (3.4) 137 (42.0) 62 (53–73) 10.9 (14.7) 38,669 (26,532)
Lip 380 (3.9) 85 (22.4) 83 (76–88) 2.7 (6.7) 10,129 (16,495)
Oral cavity 2,035 (20.9) 886 (43.5) 64 (56–77) 10.1 (13.7) 36,883 (34,771)
Oropharynx 2,819 (29.0) 1,416 (50.2) 61 (55–70) 13.0 (14.6) 41,589 (33,641)
Hypopharynx 1,627 (16.8) 888 (54.6) 62 (55–72) 13.6 (14.4) 46,714 (35,402)
Larynx 1,799 (18.5) 676 (37.6) 67 (58–78) 8.0 (12.1) 35,309 (33,524)
Ill-deﬁned HNSCC 231 (2.4) 145 (62.8) 64 (57–77) 14.4 (14.4) 33,143 (30,967)
Cancer stage at initial treatment
Early 2,978 (30.6) 822 (27.6) 75 (61–84) 4.9 (9.8) 19,819 (23,150)
Locally advanced 5,856 (60.3) 2,861 (48.9) 62 (55–73) 12.2 (14.3) 46,791 (34,841)
Distant metastasis 880 (9.1) 773 (87.8) 62 (55–71) 22.4 (12.4) 43,377 (33,953)
Charlson Comorbidity Index at initial treatment
0 4,241 (43.6) 1,473 (34.7) 61 (54–73) 8.8 (13.7) 32,706 (32,063)
1 1,793 (18.5) 784 (43.7) 63 (57–75) 10.2 (13.5) 39,221 (34,419)
2 1,722 (17.7) 939 (54.5) 63 (56–75) 12.9 (14.1) 42,875 (34,244)
≥3 1,958 (20.2) 1,260 (64.4) 66 (58–77) 14.2 (13.3) 45,118 (35,145)
Notes: Comparison of survival (log-rank test) and years-of-life lost or costs per patient (Kruskal–Wallis test) were statistically signiﬁcant for all characteristics.
Abbreviations: HNSCC, head and neck squamous cell carcinoma.
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middle-aged patients was signiﬁcantly associated with
male gender, primary HNSCC sites of poor prognosis, a
late stage at initial treatment, and a higher rate of comor-
bidities that were all signiﬁcantly associated with
increased direct costs over 3 years.
This study provides new insights for cost-effectiveness
analyses carried in the HNSCC care setting. The majority
(60%) of patients was initially treated at a locally advanced
stage with the highest direct costs (46,791 euros over 3
years). As evidenced by the phase-of-care approach, the
economic burden in these patients was majored by the
intensity of combined-modality treatments at the initial
treatment phase (66.5% of 6,263 euros per month) as well
as supportive and palliative care following frequent relapses
Table 2 Clinical outcomes and direct costs of HNSCC, by phase-of-care
Characteristics of incident patients
diagnosed with HNSCC in 2010–
2012 (N=53,255)
Initial treatment Follow-up care in patients
initially treated at early or
locally advanced stage
Early stage Locally
advanced
stage
Distant
metastasis
Relapse
treatment
Continuing
care (without
relapse)
All patients by phase-of-care, n (%) 15,747 (29.6) 32,723 (61.4) 4,785 (9.0) 13,375 (25.1) 26,496 (49.8)
Gender, n (%)
Men 11,414 (72.5) 26,296 (80.4) 3,938 (82.3) 10,883 (81.4) 20,114 (75.9)
Women 4,333 (27.5) 6,427 (19.6) 847 (17.7) 2,492 (18.6) 6,382 (24.1)
Age at HNSCC diagnosis, n (%)
<65 years old 7,762 (49.3) 21,767 (66.5) 2,978 (62.2) 9,291 (69.5) 16,253 (61.3)
65+ years old 7,985 (50.7) 10,956 (33.5) 1,807 (37.8) 4,084 (30.5) 10,243 (38.7)
HNSCC site at diagnosis, n (%)
Nasal cavity / paranasal sinuses 1,266 (8.0) 1,303 (4.0) 285 (6.0) 612 (4.6) 1,567 (5.9)
Nasopharynx 389 (2.5) 1,187 (3.6) 205 (4.3) 418 (3.1) 859 (3.2)
Lip 1,857 (11.8) 257 (0.8) 43 (0.9) 151 (1.1) 1,788 (6.8)
Oral cavity 3,906 (19.9) 6,372 (19.5) 805 (16.8) 2,895 (21.6) 5,612 (21.2)
Oropharynx 2,787 (10.5) 11,079 (33.9) 1,514 (31.6) 4,351 (32.6) 6,862 (25.9)
Hypopharynx 1,411 (9.1) 6,562 (20.0) 1,075 (22.5) 2,723 (20.4) 3,709 (14.0)
Larynx 4,131 (26.2) 4,793 (14.6) 668 (13.9) 1,953 (14.6) 5,557 (21.0)
Ill-deﬁned HNSCC – 1,170 (3.6) 190 (4.0) 272 (2.0) 542 (2.0)
Charlson Comorbidity Index, n (%)
0 8,231 (52.3) 13,954 (42.6) 1,143 (23.9) 4,736 (35.4) 13,614 (51.4)
1 2,917 (18.5) 5,966 (18.2) 560 (11.7) 2,643 (19.7) 5,200 (19.6)
2 1,971 (12.5) 5,818 (17.8) 1,210 (25.3) 2,483 (18.6) 3,180 (12.0)
≥3 2,628 (16.7) 6,985 (21.4) 1,872 (39.1) 3,513 (26.3) 4,502 (17.0)
Clinical outcomes
Follow-up, mean (SD) months 5.6 (1.4) 5.5 (1.4) 9.4 (9.2) 9.6 (8.7) 16.6 (10.8)
Death rate over the follow-up, n (%) 1,641 (10.4) 5,298 (16.2) 3,855 (80.6) 6,551 (49.0) 3,211 (12.1)
Relapse rate at 18 months, cumulative inci-
dence (95% CI)
13.4 (12.9–13.9) 32.5 (32.0–33.0) – – –
Direct costs per month, mean (SD) euros 2,566 (3,156) 6,263 (3,334) 7,340 (2,635) 5,320 (3,365) 435 (1,236)
Notes: Cumulative incidence functions of relapse during continuing care were estimated for patients initially treated at early or advanced stage, while taking into account
the competing risk of death. Patients with distant metastasis at initial treatment had a high death rate and direct costs per month were computed to the end of follow-up
rather than the ﬁrst six months
Abbreviations: HNSCC, head and neck squamous cell carcinoma.
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(54% of 5,320 euros per month). Such heterogeneity in both
outcomes and costs over time supports the identiﬁcation of
a relapse state in cost-effectiveness analyses. In addition, we
found that expensive-targeted therapy cetuximab accounted
for a relatively low proportion (5%) of prevalent direct
costs, eg, about half costs of medical transportation to/
from hospital. It questions whether any cost-effectiveness
threshold may be meaningful to assess the value of new
salvage therapy.35,36
The strengths of our study outline its limitations. Indeed,
this study is based on a nationwide sample of all incident cases
of HNSCC discharged from French hospitals, but all measure-
ments relied on administrative records. Classiﬁcation of
malignant tumors based on TNM staging [extent of the
tumor (T), extent of spread to the lymph nodes (N), and
presence of metastasis (M)] is not recorded in the standardized
discharge summary. Therefore, we constructed a composite
variable to identify a HNSCC stage at initial treatment and
relapse in the follow-up and found consistent results with
cancer registries.3 Regarding valuation methods, we made
several assumptions in the private sector by using public
National DRG-related tariffs and imputing radiation therapy.
Presumably, the impact was limited on the study results as the
DRG system is the same in both sectors andmost (69%) direct
costs were eventually bored by the public sector. Direct costs
assessed in this study covered all costs related to hospital care,
while outpatient costs related to physician visits and lab/ima-
ging exams should also be considered. However, outpatient
2 500
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1 500
1 510
1 000
500
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Initial treatment at
early stage
621
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366
421
606
942
1074
1105
859
704
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322 345
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1321
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1721
2322
Diagnostic
Surgery (including
reconstructive surgery)
Radiation therapy
(private sector only)
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(ilncluding cetuximab)
cetuximab only
Supportive care
Palliative care
Medical transportation
to/from hospital (all)
Medical transportation
(all radiation therapy)
Medical transportation
(all chemotherapy)
Radiation therapy
(including private
sector)
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44
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182 190
18
339
295
107
382
481
Initial treatment at
locally advanced stage
Initial treatment with
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Relapse treatment Continuing care
(without relapse)
Є
Є
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Є
Figure 2 Mean monthly costs of headand neck squamous cell carcinoma (HNSCC), by phase-of-care and main cost category.
Notes: Direct costs include reimbursements to public/private hospitals in acute and post-acute care, out-of-pocket expenses for inpatient stays, radiation therapy imputed
in the private sector, and medical transportation to/from hospital.
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costs are minimal relative to hospital costs, in particular in
France.
Conclusion
HNSCC care was associated with a substantial clinical and
economic burden in France in 2010–2012. Less than one-third
of HNSCC patients were treated at early stage. Increasing
prevention and early detection strategies are likely cost-effec-
tive to decrease the burden of HNSCC. The study results also
suggest that the economic evaluation of salvage therapy with
new immunotherapy should be country-speciﬁc and put in the
global context of HNSCC prognosis and direct costs.
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